tiprankstipranks
Karyopharm sees Q4 revenue $33.6M, consensus $37.64M
The Fly

Karyopharm sees Q4 revenue $33.6M, consensus $37.64M

Expects U.S. XPOVIO net product revenue to be approximately $25M for the fourth quarter 2023 and approximately $112M for the full year 2023, meeting company’s guidance. Cash, cash equivalents, restricted cash and investments as of December 31, 2023 was approximately $192M, enabling an expected cash runway into late 2025.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles